| NCT04266301 |
Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) |
https://ClinicalTrials.gov/show/NCT04266301 |
Recruiting |
Novartis |
2027-08-26 |
| NCT04139434 |
Dose-escalation Study of Oral Administration of LP-108 in Patients With Relapsed or Refractory Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) |
https://ClinicalTrials.gov/show/NCT04139434 |
Recruiting |
Newave Pharmaceutical Inc |
2022-06-30 |
| NCT03912064 |
A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT |
https://ClinicalTrials.gov/show/NCT03912064 |
Recruiting |
Dana-Farber Cancer Institute |
2022-04-26 |
| NCT03383575 |
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome |
https://ClinicalTrials.gov/show/NCT03383575 |
Recruiting |
M.D. Anderson Cancer Center |
2022-02-28 |
| NCT03588078 |
Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine |
https://ClinicalTrials.gov/show/NCT03588078 |
Active, not recruiting |
Groupe Francophone des Myelodysplasies |
2020-05-01 |
| NCT03333486 |
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer |
https://ClinicalTrials.gov/show/NCT03333486 |
Recruiting |
Roswell Park Cancer Institute |
2022-09-06 |
| NCT03326921 |
HA-1 T TCR T Cell Immunotherapy for the Treating of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT03326921 |
Recruiting |
Fred Hutchinson Cancer Research Center |
2023-12-16 |
| NCT03306264 |
Study of ASTX727 vs IV Decitabine in MDS, CMML, and AML |
https://ClinicalTrials.gov/show/NCT03306264 |
Active, not recruiting |
Astex Pharmaceuticals, Inc. |
2019-03-31 |
| NCT03289910 |
Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia |
https://ClinicalTrials.gov/show/NCT03289910 |
Recruiting |
National Cancer Institute (NCI) |
2021-06-01 |
| NCT03268954 |
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) |
https://ClinicalTrials.gov/show/NCT03268954 |
Active, not recruiting |
Takeda |
2020-11-30 |
| NCT03263637 |
Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies |
https://ClinicalTrials.gov/show/NCT03263637 |
Active, not recruiting |
AstraZeneca |
2021-12-31 |
| NCT03192397 |
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT03192397 |
Recruiting |
Roswell Park Cancer Institute |
2021-07-01 |
| NCT03190915 |
Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia |
https://ClinicalTrials.gov/show/NCT03190915 |
Recruiting |
National Cancer Institute (NCI) |
2021-12-31 |
| NCT03175978 |
IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome |
https://ClinicalTrials.gov/show/NCT03175978 |
Recruiting |
IGF Oncology, LLC |
2020-06-30 |
| NCT03128034 |
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia |
https://ClinicalTrials.gov/show/NCT03128034 |
Recruiting |
Fred Hutchinson Cancer Research Center |
2021-06-30 |
| NCT03096782 |
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma |
https://ClinicalTrials.gov/show/NCT03096782 |
Recruiting |
M.D. Anderson Cancer Center |
2020-10-31 |
| NCT03072043 |
Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms |
https://ClinicalTrials.gov/show/NCT03072043 |
Active, not recruiting |
H. Lee Moffitt Cancer Center and Research Institute |
2020-06-30 |
| NCT03047993 |
Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome |
https://ClinicalTrials.gov/show/NCT03047993 |
Recruiting |
M.D. Anderson Cancer Center |
2022-04-01 |
| NCT03018223 |
Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT |
https://ClinicalTrials.gov/show/NCT03018223 |
Active, not recruiting |
H. Lee Moffitt Cancer Center and Research Institute |
2018-12-15 |
| NCT02960646 |
Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT02960646 |
Recruiting |
M.D. Anderson Cancer Center |
2020-11-30 |
| NCT02935361 |
Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed |
https://ClinicalTrials.gov/show/NCT02935361 |
Recruiting |
University of Southern California |
2020-11-02 |
| NCT02907359 |
Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs |
https://ClinicalTrials.gov/show/NCT02907359 |
Active, not recruiting |
Astex Pharmaceuticals, Inc. |
2020-06-30 |
| NCT02841540 |
A Phase 1 Study to Evaluate H3B-8800 in Participants With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia |
https://ClinicalTrials.gov/show/NCT02841540 |
Active, not recruiting |
Eisai Inc. |
2020-12-01 |
| NCT02807272 |
Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia |
https://ClinicalTrials.gov/show/NCT02807272 |
Active, not recruiting |
Kura Oncology, Inc. |
2021-01-15 |
| NCT02727803 |
Personalized NK Cell Therapy After Chemotherapy and Cord Blood Transplant in Treating Patients With Myelodysplastic Syndrome, Leukemia, Lymphoma or Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT02727803 |
Recruiting |
M.D. Anderson Cancer Center |
2020-05-19 |
| NCT02666950 |
WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome |
https://ClinicalTrials.gov/show/NCT02666950 |
Completed |
Mayo Clinic |
2018-09-25 |
| NCT02649764 |
Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome |
https://ClinicalTrials.gov/show/NCT02649764 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2021-05-31 |
| NCT02610777 |
An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML) |
https://ClinicalTrials.gov/show/NCT02610777 |
Active, not recruiting |
Takeda |
2019-09-04 |
| NCT02756572 |
Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms |
https://ClinicalTrials.gov/show/NCT02756572 |
Completed |
University of Washington |
2020-03-01 |
| NCT03404193 |
Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome |
https://ClinicalTrials.gov/show/NCT03404193 |
Recruiting |
M.D. Anderson Cancer Center |
2023-12-31 |
| NCT02566304 |
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT02566304 |
Recruiting |
Thomas Jefferson University |
2020-07-23 |
| NCT02556931 |
Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies |
https://ClinicalTrials.gov/show/NCT02556931 |
Active, not recruiting |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2021-07-31 |
| NCT02553941 |
Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome |
https://ClinicalTrials.gov/show/NCT02553941 |
Active, not recruiting |
University of California, Davis |
2020-11-30 |
| NCT02546284 |
Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML) |
https://ClinicalTrials.gov/show/NCT02546284 |
Completed |
Humanigen, Inc. |
2020-02-29 |
| NCT02530034 |
Hu8F4 in Treating Patients With Advanced Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT02530034 |
Recruiting |
M.D. Anderson Cancer Center |
2022-01-31 |
| NCT02397720 |
Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia |
https://ClinicalTrials.gov/show/NCT02397720 |
Recruiting |
M.D. Anderson Cancer Center |
2020-04-30 |
| NCT02268253 |
Tagraxofusp (SL-401) in Patients With CMML or MF |
https://ClinicalTrials.gov/show/NCT02268253 |
Recruiting |
Stemline Therapeutics, Inc. |
2021-07-31 |
| NCT02210858 |
Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders |
https://ClinicalTrials.gov/show/NCT02210858 |
Completed |
National Cancer Institute (NCI) |
2004-11-12 |
| NCT02201329 |
Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia |
https://ClinicalTrials.gov/show/NCT02201329 |
Completed |
Boehringer Ingelheim |
2015-01-31 |
| NCT02197676 |
A Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Marrow Blasts or Chronic Myelomonocytic Leukemia Type 2 Not Responding to Azacitidine or Decitabine After at Least 6 Courses or Relapsing After a Response |
https://ClinicalTrials.gov/show/NCT02197676 |
Completed |
Groupe Francophone des Myelodysplasies |
2016-02-06 |
| NCT02190695 |
Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS |
https://ClinicalTrials.gov/show/NCT02190695 |
Active, not recruiting |
Fox Chase Cancer Center |
2026-07-01 |
| NCT02129101 |
Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies |
https://ClinicalTrials.gov/show/NCT02129101 |
Completed |
Mayo Clinic |
2016-12-31 |
| NCT02121418 |
Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm |
https://ClinicalTrials.gov/show/NCT02121418 |
Completed |
University of Washington |
2017-02-08 |
| NCT01307579 |
Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia |
https://ClinicalTrials.gov/show/NCT01307579 |
Active, not recruiting |
Children’s Oncology Group |
2018-06-30 |
| NCT01305200 |
Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT01305200 |
Completed |
Children’s Oncology Group |
2015-06-30 |
| NCT01300572 |
Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS |
https://ClinicalTrials.gov/show/NCT01300572 |
Completed |
Fred Hutchinson Cancer Research Center |
2017-10-29 |
| NCT03358719 |
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia |
https://ClinicalTrials.gov/show/NCT03358719 |
Active, not recruiting |
Roswell Park Cancer Institute |
2020-02-27 |
| NCT01926587 |
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine |
https://ClinicalTrials.gov/show/NCT01926587 |
Active, not recruiting |
Onconova Therapeutics, Inc. |
2020-09-30 |
| NCT01894477 |
Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia |
https://ClinicalTrials.gov/show/NCT01894477 |
Active, not recruiting |
Fred Hutchinson Cancer Research Center |
2017-01-09 |
| NCT01885689 |
Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia |
https://ClinicalTrials.gov/show/NCT01885689 |
Active, not recruiting |
City of Hope Medical Center |
2021-12-31 |
| NCT01872819 |
Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay |
https://ClinicalTrials.gov/show/NCT01872819 |
Completed |
University of Washington |
2014-11-30 |
| NCT01842646 |
Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS) |
https://ClinicalTrials.gov/show/NCT01842646 |
Active, not recruiting |
H. Lee Moffitt Cancer Center and Research Institute |
2016-01-31 |
| NCT01834248 |
DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia |
https://ClinicalTrials.gov/show/NCT01834248 |
Completed |
Roswell Park Cancer Institute |
2015-06-09 |
| NCT01824693 |
Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia |
https://ClinicalTrials.gov/show/NCT01824693 |
Completed |
Children’s Oncology Group |
2017-12-31 |
| NCT01823198 |
Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies |
https://ClinicalTrials.gov/show/NCT01823198 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2020-06-30 |
| NCT01812252 |
Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT01812252 |
Recruiting |
Fred Hutchinson Cancer Research Center |
2021-04-01 |
| NCT01789255 |
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT01789255 |
Completed |
National Cancer Institute (NCI) |
2014-03-31 |
| NCT01776723 |
A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib |
https://ClinicalTrials.gov/show/NCT01776723 |
Active, not recruiting |
H. Lee Moffitt Cancer Center and Research Institute |
2018-11-28 |
| NCT01773395 |
GVAX vs. Placebo for MDS/AML After Allo HSCT |
https://ClinicalTrials.gov/show/NCT01773395 |
Active, not recruiting |
Dana-Farber Cancer Institute |
2021-06-01 |
| NCT01772420 |
Lenalidomide and Eltrombopag Olamine in Treating Patients With Symptomatic Anemia in Low or Intermediate Myelodysplastic Syndrome |
https://ClinicalTrials.gov/show/NCT01772420 |
Recruiting |
Albert Einstein College of Medicine |
2020-01-31 |
| NCT01760655 |
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01760655 |
Recruiting |
Thomas Jefferson University |
2021-03-31 |
| NCT01757639 |
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia |
https://ClinicalTrials.gov/show/NCT01757639 |
Completed |
National Cancer Institute (NCI) |
2016-12-31 |
| NCT01736683 |
Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML) |
https://ClinicalTrials.gov/show/NCT01736683 |
Completed |
Celgene |
2018-04-30 |
| NCT01664897 |
Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia |
https://ClinicalTrials.gov/show/NCT01664897 |
Completed |
M.D. Anderson Cancer Center |
2018-10-25 |
| NCT01613976 |
A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients |
https://ClinicalTrials.gov/show/NCT01613976 |
Completed |
Novartis |
2014-05-31 |
| NCT01588015 |
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT01588015 |
Active, not recruiting |
City of Hope Medical Center |
2021-11-30 |
| NCT01529827 |
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01529827 |
Completed |
Roswell Park Cancer Institute |
2015-05-28 |
| NCT01522976 |
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia |
https://ClinicalTrials.gov/show/NCT01522976 |
Active, not recruiting |
National Cancer Institute (NCI) |
2015-06-01 |
| NCT01519011 |
Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine |
https://ClinicalTrials.gov/show/NCT01519011 |
Completed |
Celgene |
2012-12-31 |
| NCT01484015 |
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia |
https://ClinicalTrials.gov/show/NCT01484015 |
Completed |
Wake Forest University Health Sciences |
2012-06-30 |
| NCT01427881 |
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT01427881 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-06-30 |
| NCT01404741 |
5-azacytidine Treatment Versus 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Myelodysplastic Syndrome (MDS) |
https://ClinicalTrials.gov/show/NCT01404741 |
Active, not recruiting |
Universitätsklinikum Hamburg-Eppendorf |
2020-05-31 |
| NCT01398462 |
Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients |
https://ClinicalTrials.gov/show/NCT01398462 |
Completed |
JW Pharmaceutical |
2015-12-31 |
| NCT01384513 |
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT01384513 |
Recruiting |
Thomas Jefferson University |
2020-12-31 |
| NCT01350947 |
A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia |
https://ClinicalTrials.gov/show/NCT01350947 |
Completed |
University of Utah |
2014-09-30 |
| NCT01338987 |
Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation |
https://ClinicalTrials.gov/show/NCT01338987 |
Active, not recruiting |
National Institutes of Health Clinical Center (CC) |
2017-12-01 |
| NCT04160052 |
Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome |
https://ClinicalTrials.gov/show/NCT04160052 |
Recruiting |
M.D. Anderson Cancer Center |
2020-12-31 |
| NCT03999723 |
Combining Active and Passive DNA Hypomethylation |
https://ClinicalTrials.gov/show/NCT03999723 |
Recruiting |
Rigshospitalet, Denmark |
2023-03-31 |
| NCT03922100 |
Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML |
https://ClinicalTrials.gov/show/NCT03922100 |
Recruiting |
Nerviano Medical Sciences |
2023-09-30 |
| NCT03896269 |
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia |
https://ClinicalTrials.gov/show/NCT03896269 |
Recruiting |
M.D. Anderson Cancer Center |
2020-12-31 |
| NCT03873311 |
Azacytidine + HAG Regimen in Elderly Patients With Myeloid Malignancy. |
https://ClinicalTrials.gov/show/NCT03873311 |
Recruiting |
Shenzhen Second People’s Hospital |
2021-12-01 |
| NCT03814005 |
A Study of Pevonedistat in Combination With Azacitidine in Participants With Higher-risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myelogenous Leukemia (AML) With Severe Renal Impairment or Mild Hepatic Impairment |
https://ClinicalTrials.gov/show/NCT03814005 |
Active, not recruiting |
Takeda |
2020-10-05 |
| NCT03813186 |
Effect of Food on Blood Levels of ASTX727 |
https://ClinicalTrials.gov/show/NCT03813186 |
Completed |
Astex Pharmaceuticals, Inc. |
2019-06-14 |
| NCT03746041 |
A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes |
https://ClinicalTrials.gov/show/NCT03746041 |
Recruiting |
University of Rochester |
2021-11-01 |
| NCT03734601 |
Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation |
https://ClinicalTrials.gov/show/NCT03734601 |
Active, not recruiting |
Stanford University |
2020-11-30 |
| NCT03722407 |
Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion |
https://ClinicalTrials.gov/show/NCT03722407 |
Recruiting |
H. Lee Moffitt Cancer Center and Research Institute |
2022-05-01 |
| NCT03683433 |
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation |
https://ClinicalTrials.gov/show/NCT03683433 |
Recruiting |
M.D. Anderson Cancer Center |
2021-09-20 |
| NCT03682029 |
Epigenetics, Vitamin C, and Abnormal Blood Cell Formation - Vitamin C in Patients With Low-Risk Myeloid Malignancies |
https://ClinicalTrials.gov/show/NCT03682029 |
Recruiting |
Rigshospitalet, Denmark |
2020-12-01 |
| NCT03672539 |
Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome |
https://ClinicalTrials.gov/show/NCT03672539 |
Recruiting |
M.D. Anderson Cancer Center |
2020-06-30 |
| NCT03670966 |
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome |
https://ClinicalTrials.gov/show/NCT03670966 |
Recruiting |
Fred Hutchinson Cancer Research Center |
2023-09-01 |
| NCT03613532 |
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant for AML, MDS, and MDS/MPN |
https://ClinicalTrials.gov/show/NCT03613532 |
Recruiting |
Dana-Farber Cancer Institute |
2020-10-01 |
| NCT03515512 |
IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT03515512 |
Recruiting |
Massachusetts General Hospital |
2021-05-31 |
| NCT03493646 |
Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486 |
https://ClinicalTrials.gov/show/NCT03493646 |
Recruiting |
Kirby Institute |
2020-12-31 |
| NCT01251627 |
Multicenter Study to Assess the Efficacy of Decitabine in the Treatment of Chronic Myelomonocytic Leukemia |
https://ClinicalTrials.gov/show/NCT01251627 |
Completed |
Fondazione Italiana Sindromi Mielodisplastiche Onlus |
2011-12-31 |
| NCT01235117 |
Azacitidine in Treating Patients With Chronic Myelomonocytic Leukemia |
https://ClinicalTrials.gov/show/NCT01235117 |
Completed |
National Cancer Institute (NCI) |
2012-12-31 |
| NCT01233921 |
Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT01233921 |
Completed |
Fred Hutchinson Cancer Research Center |
2012-07-31 |
| NCT01231919 |
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia |
https://ClinicalTrials.gov/show/NCT01231919 |
Completed |
National Cancer Institute (NCI) |
2013-04-30 |
| NCT01177371 |
High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01177371 |
Completed |
Case Comprehensive Cancer Center |
2000-02-29 |
| NCT01169012 |
PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias |
https://ClinicalTrials.gov/show/NCT01169012 |
Completed |
UNC Lineberger Comprehensive Cancer Center |
2012-04-30 |
| NCT01165996 |
Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome |
https://ClinicalTrials.gov/show/NCT01165996 |
Completed |
Case Comprehensive Cancer Center |
2011-12-31 |
| NCT01139970 |
Veliparib and Temozolomide in Treating Patients With Acute Leukemia |
https://ClinicalTrials.gov/show/NCT01139970 |
Active, not recruiting |
National Cancer Institute (NCI) |
2014-03-21 |
| NCT01101880 |
Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm |
https://ClinicalTrials.gov/show/NCT01101880 |
Completed |
University of Washington |
2013-06-30 |
| NCT01098084 |
Decitabine in Patients With Chronic Myelomonocytic Leukemia (CMML) |
https://ClinicalTrials.gov/show/NCT01098084 |
Completed |
Groupe Francophone des Myelodysplasies |
2009-06-30 |
| NCT01083706 |
Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT01083706 |
Completed |
Fred Hutchinson Cancer Research Center |
2013-12-31 |
| NCT01053494 |
Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer |
https://ClinicalTrials.gov/show/NCT01053494 |
Completed |
Wake Forest University Health Sciences |
2012-02-29 |
| NCT01048034 |
Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) |
https://ClinicalTrials.gov/show/NCT01048034 |
Completed |
Nordic MDS Group |
2012-08-31 |
| NCT01020539 |
Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia |
https://ClinicalTrials.gov/show/NCT01020539 |
Active, not recruiting |
Columbia University |
2011-07-20 |
| NCT00988715 |
Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome |
https://ClinicalTrials.gov/show/NCT00988715 |
Completed |
Fred Hutchinson Cancer Research Center |
2015-01-31 |
| NCT00946647 |
A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML). |
https://ClinicalTrials.gov/show/NCT00946647 |
Completed |
Novartis |
2019-04-29 |
| NCT00890747 |
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy |
https://ClinicalTrials.gov/show/NCT00890747 |
Completed |
National Cancer Institute (NCI) |
2011-05-31 |
| NCT00860574 |
Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia |
https://ClinicalTrials.gov/show/NCT00860574 |
Completed |
Fred Hutchinson Cancer Research Center |
2013-02-28 |
| NCT00856388 |
Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders |
https://ClinicalTrials.gov/show/NCT00856388 |
Completed |
Roswell Park Cancer Institute |
2012-08-09 |
| NCT00843882 |
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia |
https://ClinicalTrials.gov/show/NCT00843882 |
Active, not recruiting |
National Cancer Institute (NCI) |
2019-07-08 |
| NCT01831232 |
Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes |
https://ClinicalTrials.gov/show/NCT01831232 |
Completed |
Fred Hutchinson Cancer Research Center |
2015-02-28 |
| NCT00809250 |
Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After Allogeneic Hematopoetic Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT00809250 |
Active, not recruiting |
Dana-Farber Cancer Institute |
2011-05-31 |
| NCT01892371 |
Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome |
https://ClinicalTrials.gov/show/NCT01892371 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2020-11-30 |
| NCT03878524 |
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial |
https://ClinicalTrials.gov/show/NCT03878524 |
Recruiting |
OHSU Knight Cancer Institute |
2022-02-27 |
| NCT01928537 |
Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine |
https://ClinicalTrials.gov/show/NCT01928537 |
Completed |
Onconova Therapeutics, Inc. |
2017-06-29 |
| NCT01241500 |
Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts |
https://ClinicalTrials.gov/show/NCT01241500 |
Completed |
Onconova Therapeutics, Inc. |
2018-10-03 |
| NCT02472691 |
Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCT |
https://ClinicalTrials.gov/show/NCT02472691 |
Completed |
Heinrich-Heine University, Duesseldorf |
2020-04-23 |
| NCT02367456 |
A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients |
https://ClinicalTrials.gov/show/NCT02367456 |
Active, not recruiting |
Pfizer |
2020-01-29 |
| NCT02029950 |
Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome |
https://ClinicalTrials.gov/show/NCT02029950 |
Active, not recruiting |
National Cancer Institute (NCI) |
2020-07-04 |
| NCT01629082 |
Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia |
https://ClinicalTrials.gov/show/NCT01629082 |
Completed |
National Institutes of Health Clinical Center (CC) |
2015-10-27 |
| NCT04093570 |
An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) |
https://ClinicalTrials.gov/show/NCT04093570 |
Enrolling by invitation |
Astex Pharmaceuticals, Inc. |
2021-03-31 |
| NCT03862157 |
Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia |
https://ClinicalTrials.gov/show/NCT03862157 |
Recruiting |
M.D. Anderson Cancer Center |
2024-01-01 |
| NCT00761722 |
Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT00761722 |
Completed |
Celgene |
2016-04-06 |
| NCT00744536 |
Efficacy Study of Revlimid® and Low Dose Continuously Administered Melphalan to Treat High Risk MDS |
https://ClinicalTrials.gov/show/NCT00744536 |
Completed |
Sunnybrook Health Sciences Centre |
2012-01-31 |
| NCT00719836 |
A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies |
https://ClinicalTrials.gov/show/NCT00719836 |
Completed |
S*BIO |
2012-01-31 |
| NCT00666588 |
Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia |
https://ClinicalTrials.gov/show/NCT00666588 |
Completed |
National Cancer Institute (NCI) |
2012-12-31 |
| NCT00589316 |
Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome |
https://ClinicalTrials.gov/show/NCT00589316 |
Active, not recruiting |
Fred Hutchinson Cancer Research Center |
2016-10-01 |
| NCT00588991 |
Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders |
https://ClinicalTrials.gov/show/NCT00588991 |
Active, not recruiting |
National Cancer Institute (NCI) |
2014-02-01 |
| NCT00528983 |
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia |
https://ClinicalTrials.gov/show/NCT00528983 |
Completed |
Celgene |
2013-07-31 |
| NCT00489203 |
Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00489203 |
Completed |
Fred Hutchinson Cancer Research Center |
2010-11-30 |
| NCT00462605 |
MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia |
https://ClinicalTrials.gov/show/NCT00462605 |
Completed |
National Cancer Institute (NCI) |
2011-03-31 |
| NCT00451048 |
Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia |
https://ClinicalTrials.gov/show/NCT00451048 |
Completed |
National Cancer Institute (NCI) |
2011-09-30 |
| NCT01093586 |
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01093586 |
Completed |
Case Comprehensive Cancer Center |
2015-12-31 |
| NCT00408681 |
Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00408681 |
Completed |
Fred Hutchinson Cancer Research Center |
2010-11-30 |
| NCT00397813 |
Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders |
https://ClinicalTrials.gov/show/NCT00397813 |
Completed |
Fred Hutchinson Cancer Research Center |
2017-09-30 |
| NCT00392353 |
Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia |
https://ClinicalTrials.gov/show/NCT00392353 |
Active, not recruiting |
National Cancer Institute (NCI) |
2021-06-30 |
| NCT00799461 |
Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications |
https://ClinicalTrials.gov/show/NCT00799461 |
Completed |
Fred Hutchinson Cancer Research Center |
2011-11-30 |
| NCT00381550 |
3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia |
https://ClinicalTrials.gov/show/NCT00381550 |
Completed |
National Cancer Institute (NCI) |
2011-03-31 |
| NCT00357708 |
Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases |
https://ClinicalTrials.gov/show/NCT00357708 |
Completed |
National Cancer Institute (NCI) |
2009-10-31 |
| NCT00357305 |
Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders |
https://ClinicalTrials.gov/show/NCT00357305 |
Completed |
National Cancer Institute (NCI) |
2011-11-30 |
| NCT00351975 |
Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases |
https://ClinicalTrials.gov/show/NCT00351975 |
Completed |
National Cancer Institute (NCI) |
2013-03-31 |
| NCT00313586 |
Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia |
https://ClinicalTrials.gov/show/NCT00313586 |
Completed |
National Cancer Institute (NCI) |
2013-07-31 |
| NCT00299156 |
Oral Clofarabine Study in Patients With Myelodysplastic Syndrome |
https://ClinicalTrials.gov/show/NCT00299156 |
Completed |
M.D. Anderson Cancer Center |
2012-12-31 |
| NCT00283114 |
A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome |
https://ClinicalTrials.gov/show/NCT00283114 |
Completed |
Seattle Genetics, Inc. |
2010-01-31 |
| NCT00255346 |
Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) |
https://ClinicalTrials.gov/show/NCT00255346 |
Completed |
M.D. Anderson Cancer Center |
2017-03-03 |
| NCT00171912 |
Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes |
https://ClinicalTrials.gov/show/NCT00171912 |
Completed |
Novartis |
2012-01-31 |
| NCT00167219 |
Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML) |
https://ClinicalTrials.gov/show/NCT00167219 |
Recruiting |
Masonic Cancer Center, University of Minnesota |
2020-12-31 |
| NCT00136409 |
A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML) |
https://ClinicalTrials.gov/show/NCT00136409 |
Completed |
Dana-Farber Cancer Institute |
2005-08-31 |
| NCT00119366 |
Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome |
https://ClinicalTrials.gov/show/NCT00119366 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-08-31 |
| NCT00118352 |
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00118352 |
Completed |
Fred Hutchinson Cancer Research Center |
2010-07-31 |
| NCT00112593 |
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer |
https://ClinicalTrials.gov/show/NCT00112593 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-11-30 |
| NCT00101179 |
MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia |
https://ClinicalTrials.gov/show/NCT00101179 |
Completed |
National Cancer Institute (NCI) |
2011-04-20 |
| NCT00098423 |
Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes |
https://ClinicalTrials.gov/show/NCT00098423 |
Completed |
National Cancer Institute (NCI) |
2009-05-31 |
| NCT00096122 |
Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia |
https://ClinicalTrials.gov/show/NCT00096122 |
Completed |
National Cancer Institute (NCI) |
2006-09-30 |
| NCT00095797 |
XK469R in Treating Patients With Refractory Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00095797 |
Completed |
National Cancer Institute (NCI) |
2007-03-31 |
| NCT00087204 |
Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia |
https://ClinicalTrials.gov/show/NCT00087204 |
Completed |
National Cancer Institute (NCI) |
2007-01-31 |
| NCT00084916 |
CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase |
https://ClinicalTrials.gov/show/NCT00084916 |
Completed |
National Cancer Institute (NCI) |
2007-03-31 |
| NCT00006251 |
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer |
https://ClinicalTrials.gov/show/NCT00006251 |
Completed |
Fred Hutchinson Cancer Research Center |
2005-09-30 |
| NCT00005942 |
Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy |
https://ClinicalTrials.gov/show/NCT00005942 |
Completed |
National Cancer Institute (NCI) |
2000-12-31 |
| NCT00079313 |
Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia |
https://ClinicalTrials.gov/show/NCT00079313 |
Completed |
National Institutes of Health Clinical Center (CC) |
2006-12-30 |
| NCT00078858 |
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00078858 |
Completed |
Fred Hutchinson Cancer Research Center |
2006-01-31 |
| NCT00015990 |
Thalidomide in Treating Patients With Myelodysplastic Syndrome |
https://ClinicalTrials.gov/show/NCT00015990 |
Completed |
National Cancer Institute (NCI) |
2007-02-28 |
| NCT00008177 |
Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes |
https://ClinicalTrials.gov/show/NCT00008177 |
Completed |
Fred Hutchinson Cancer Research Center |
2009-03-21 |
| NCT00005845 |
Tipifarnib in Treating Patients With Myelodysplastic Syndromes |
https://ClinicalTrials.gov/show/NCT00005845 |
Completed |
National Cancer Institute (NCI) |
2009-09-30 |
| NCT00067808 |
Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS) |
https://ClinicalTrials.gov/show/NCT00067808 |
Completed |
M.D. Anderson Cancer Center |
2009-05-31 |
| NCT00052832 |
Doxercalciferol in Treating Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia |
https://ClinicalTrials.gov/show/NCT00052832 |
Completed |
University of Wisconsin, Madison |
2005-07-31 |
| NCT00039416 |
Imatinib Mesylate in Treating Patients With Myelofibrosis |
https://ClinicalTrials.gov/show/NCT00039416 |
Completed |
National Cancer Institute (NCI) |
2007-08-31 |
| NCT00795769 |
Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00795769 |
Completed |
Fred Hutchinson Cancer Research Center |
2009-06-09 |
| NCT00027820 |
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer |
https://ClinicalTrials.gov/show/NCT00027820 |
Completed |
Fred Hutchinson Cancer Research Center |
2004-09-30 |
| NCT00025662 |
Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS |
https://ClinicalTrials.gov/show/NCT00025662 |
Completed |
National Institutes of Health Clinical Center (CC) |
2008-02-29 |
| NCT00025415 |
Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction |
https://ClinicalTrials.gov/show/NCT00025415 |
Completed |
National Cancer Institute (NCI) |
2005-01-31 |
| NCT00025038 |
Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic Leukemia |
https://ClinicalTrials.gov/show/NCT00025038 |
Completed |
National Cancer Institute (NCI) |
2007-10-31 |
| NCT00014235 |
Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00014235 |
Completed |
Fred Hutchinson Cancer Research Center |
2005-02-28 |
| NCT00012376 |
Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer |
https://ClinicalTrials.gov/show/NCT00012376 |
Completed |
National Cancer Institute (NCI) |
2010-01-31 |
| NCT00006363 |
Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia |
https://ClinicalTrials.gov/show/NCT00006363 |
Completed |
National Cancer Institute (NCI) |
2005-06-30 |
| NCT00002798 |
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome |
https://ClinicalTrials.gov/show/NCT00002798 |
Completed |
National Cancer Institute (NCI) |
2006-09-30 |
| NCT00038675 |
Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate |
https://ClinicalTrials.gov/show/NCT00038675 |
Completed |
M.D. Anderson Cancer Center |
2013-11-30 |
| NCT00038051 |
Evaluation of the Anti-CD-33 Immunotoxin Hum-195/rGel in Patients With Advanced Myeloid Malignancies |
https://ClinicalTrials.gov/show/NCT00038051 |
Completed |
M.D. Anderson Cancer Center |
2013-02-28 |
| NCT00052520 |
Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT00052520 |
Completed |
Fred Hutchinson Cancer Research Center |
2011-04-30 |